Lupus kliniske forsøg i Illinois
14 studier for Lupus søger deltagere på steder i Illinois.
Byer i Illinois
Officiel studietekst (engelsk)
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
- Sl0044 50699, Chicago
- Sl0044 50717, Willowbrook
RekruttererFase 3
Alder 16 og opefter · Alle køn · Opdateret 2. okt. 2026 · NCT06617325Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
- Willow Rheumatology Wellness, Willowbrook
RekruttererFase 3
Alder 12 til 100 · Alle køn · Opdateret 1. okt. 2026 · NCT06133972An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
- Research Site, Chicago
- Research Site, Chicago
RekruttererFase 3
Alder 5 til 17 · Alle køn · Opdateret 30. sep. 2026 · NCT05835310A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus
- Research Site, Willowbrook
RekruttererFase 3
Alder 18 til 70 · Alle køn · Opdateret 25. sep. 2026 · NCT07430306A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
- Willow Rheumatology and Wellness PLLC, Willowbrook
RekruttererFase 3
Alder 18 til 75 · Alle køn · Opdateret 25. sep. 2026 · NCT07438496A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions and Subcutaneous Injections of ABBV-519 in Adult Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)
- Advanced Quality Medical Research /ID# 279147, Orland Park
RekruttererFase 1
Alder 18 til 75 · Alle køn · Opdateret 25. sep. 2026 · NCT07607964A Phase IIa Study of ICG318 CAR-T in Refractory Systemic Lupus Erythematosus With or Without Lupus Nephritis
- University of Chicago, Chicago
RekruttererFase 2
Alder 16 til 70 · Alle køn · Opdateret 17. sep. 2026 · NCT07328581A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE
- Research Site, Chicago
RekruttererFase 1/2
Alder 18 til 70 · Alle køn · Opdateret 10. sep. 2026 · NCT06897930A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
- The University of Chicago Medical Center, Chicago
RekruttererFase 1
Alder 18 til 74 · Alle køn · Opdateret 10. sep. 2026 · NCT07085104A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants
- Willow Rheumatology & Wellness, Willowbrook
RekruttererObservationsstudie
Alder 16 og opefter · Alle køn · Opdateret 3. sep. 2026 · NCT07175285A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
- Northwestern Medicine, Robert H. Lurie Comprehensive Cancer Center, Chicago
RekruttererFase 1
Alder 18 til 70 · Alle køn · Opdateret 28. aug. 2026 · NCT06925542RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
- Northwestern Memorial Hospital, Chicago
- The University of Chicago Medical Center, Chicago
RekruttererFase 1/2
Alder 18 til 65 · Alle køn · Opdateret 26. aug. 2026 · NCT06121297A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants With Systemic Lupus Erythematosus (SLE), Sjogren's Disease (SjD) and Rheumatoid Arthritis (RA)
- Advanced Quality Medical Research /ID# 278462, Orland Park
RekruttererFase 1
Alder 18 til 75 · Alle køn · Opdateret 10. aug. 2026 · NCT06977724Lupus Landmark Study: A Prospective Registry and Biorepository
- University of Chicago, Chicago
RekruttererObservationsstudie
Alder 18 til 110 · Alle køn · Opdateret 15. apr. 2026 · NCT05934149Fra ClinicalTrials.gov, data hentet 3. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.